Company intelligence / Profile preview
NKGen Biotech
Santa Ana, California, United Statesnkgenbiotech.com ↗
- Ownership
- Public · NKGN
- Employees
- ~63
- Development stage
- Other
01
Overview
NKGen Biotech's lead asset, troculeucel (SNK01), has demonstrated cessation of disease progression and/or cognitive improvement in over 90% of Alzheimer’s patients treated to date and is in Phase 2 trials for moderate Alzheimer’s disease. The company has completed Phase 1/2a trials in advanced refractory solid tumors and non-small cell lung cancer, with further allogeneic and CAR-NK candidates advancing toward clinical studies.[10][2][8]
- Therapeutic areas
- OncologyNeurology
- Modalities
- NK cell therapyCAR-NK cell therapyCell therapy
- Industry
- Biotech
02
Drug pipeline
8 assets7 more assets in the full pipeline.
03
Financials
- Market cap
- $1.4M
- Total revenue
- $0
- Enterprise value
- $39.6M
Beyond the preview
Go deeper on NKGen Biotech.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NKGen Biotech.